Skip to main content

Table 1 Genes commonly up-regulated throughout epileptogenesis, from the early events post-SE to the onset of recurrent spontaneous seizures.

From: Whole transcriptome analysis of the hippocampus: toward a molecular portrait of epileptogenesis

Accession No. Fold change Description
  D3 D7 Chronic  
Immune response
RN.72599 5,1 12,2 7,4 colony stimulating factor 1 receptor
RN.16195 3,7 4,0 3,2 caspase 11
RN.14655 9,6 5,6 4,1 integrin alpha l
RN.16643 4,8 4,2 3,1 fc receptor, igg, high affinity i
RN.2393 5,7 5,0 3,6 complement component 1, q subcomponent, gamma polypeptide
RN.6702 5,0 4,8 3,1 complement component 1, q subcomponent, beta polypeptide
RN.10089 4,7 4,2 3,8 cyclin-dependent kinase inhibitor 1a
RN.48861 5,2 4,8 3,6 vav 1 oncogene
RN.10748 2,9 3,9 5,5 cd4 antigen
RN.81052 2,7 4,5 4,5 complement component 4a
RN.5892 5,8 6,3 5,1 major histocompatibility complex, class ii, dm beta
RN.780 7,0 3,9 4,1 alpha-2-macroglobulin
RN.38575 3,2 3,8 3,5 neutrophil cytosolic factor 1
RN.100285 7,7 9,9 8,3 serine (or cysteine) peptidase inhibitor, clade g, member 1
RN.92197 4,7 6,5 5,9 linker for activation of t cells family, member 2
RN.3176 4,2 4,7 3,8 lymphocyte antigen 86 (predicted)
RN.101608 4,9 4,2 4,5 lymphocyte specific 1
RN.58420 3,1 2,6 2,7 similar to ikappab-zeta (predicted)
RN.16670 5,9 4,2 4,5 basic leucine zipper transcription factor, atf-like (predicted)
RN.98333 4,2 4,6 4,0 complement component 2
RN.42962 4,3 6,8 6,2 integrin beta 2
RN.105647 4,1 4,4 3,3 complement component 1, q subcomponent, alpha polypeptide
RN.37880 4,7 4,6 5,6 small inducible cytokine a4
RN.10330 6,7 4,8 5,9 cd8 antigen, beta chain
RN.10139 10,9 12,8 10,1 chemokine (c-c motif) ligand 3
RN.30043 4,8 5,7 4,9 tumor necrosis factor (ligand) superfamily, member 4
RN.3370 5,7 4,6 4,3 interferon gamma inducible protein 30
RN.90166 3,4 3,7 3,2 protein tyrosine phosphatase, receptor type, c
RN.33323 6,0 6,0 4,8 fc receptor, igg, low affinity iib
Humoral Defense Mechanism
RN.105647 4,1 4,4 3,3 complement component 1, q subcomponent, alpha polypeptide
RN.81052 2,7 4,5 4,5 complement component 4a
RN.72599 5,1 12,2 7,4 colony stimulating factor 1 receptor
RN.100285 7,7 9,9 8,3 serine (or cysteine) peptidase inhibitor, clade g, member 1
RN.2393 5,7 5,0 3,6 complement component 1, q subcomponent, gamma polypeptide
RN.10139 10,9 12,8 10,1 chemokine (c-c motif) ligand 3
RN.16670 5,9 4,2 4,5 basic leucine zipper transcription factor, atf-like (predicted)
RN.6702 5,0 4,8 3,1 complement component 1, q subcomponent, beta polypeptide
RN.42962 4,3 6,8 6,2 integrin beta 2
RN.33323 6,0 6,0 4,8 fc receptor, igg, low affinity iib
Complement and Coagulation Cascades
RN.81052 2,7 4,5 4,5 complement component 4a
RN.780 7,0 3,9 4,1 alpha-2-macroglobulin
RN.100285 7,7 9,9 8,3 serine (or cysteine) peptidase inhibitor, clade g, member 1
RN.9772 4,4 3,6 2,5 complement component 3a receptor 1
RN.6702 5,0 4,8 3,1 complement component 1, q subcomponent, beta polypeptide
RN.98333 4,2 4,6 4,0 complement component 2
RN.21393 3,7 6,5 5,7 coagulation factor x
Cell Motility
RN.66513 5,8 7,2 5,8 arachidonate 12-lipoxygenase (predicted)
RN.6282 5,0 5,0 4,8 insulin-like growth factor 1
RN.2090 3,7 3,4 2,7 actin related protein 2/3 complex, subunit 1b
RN.14655 9,6 5,6 4,1 integrin alpha l
RN.95169 3,2 3,7 3,0 abi gene family, member 3
RN.101608 4,9 4,2 4,5 lymphocyte specific 1
RN.10139 10,9 12,8 10,1 chemokine (c-c motif) ligand 3
RN.49170 4,7 4,4 3,4 suppression of tumorigenicity 14
RN.42962 4,3 6,8 6,2 integrin beta 2
Apoptosis
RN.66513 5,8 7,2 5,8 arachidonate 12-lipoxygenase (predicted)
RN.6282 5,0 5,0 4,8 insulin-like growth factor 1
RN.16195 3,7 4,0 3,2 caspase 11
RN.16643 4,8 4,2 3,1 fc receptor, igg, high affinity i
RN.101608 4,9 4,2 4,5 lymphocyte specific 1
RN.3176 4,2 4,7 3,8 lymphocyte antigen 86 (predicted)
RN.7110 6,0 4,9 4,2 receptor-interacting serine-threonine kinase 3
RN.18985 4,0 5,0 3,3 protein tyrosine phosphatase, non-receptor type 6
RN.42962 4,3 6,8 6,2 integrin beta 2
RN.10089 4,7 4,2 3,8 cyclin-dependent kinase inhibitor 1a
RN.90166 3,4 3,7 3,2 protein tyrosine phosphatase, receptor type, c
RN.10250 4,6 2,7 3,2 growth arrest and dna-damage-inducible 45 alpha
Intracellular Signaling Cascade
RN.6282 5,0 5,0 4,8 insulin-like growth factor 1
RN.68084 6,3 4,3 7,7 b-cell leukemia/lymphoma 3 (predicted)
RN.780 7,0 3,9 4,1 alpha-2-macroglobulin
RN.35286 3,4 4,0 2,9 similar to ptpl1-associated rhogap 1 (predicted)
RN.138976 3,3 3,6 2,9 sh3-domain binding protein 2
RN.19450 19,4 25,9 18,5 adenylate cyclase 7
RN.38575 3,2 3,8 3,5 neutrophil cytosolic factor 1
RN.7110 6,0 4,9 4,2 receptor-interacting serine-threonine kinase 3
RN.18985 4,0 5,0 3,3 protein tyrosine phosphatase, non-receptor type 6
RN.11534 3,6 3,8 3,2 tyro protein tyrosine kinase binding protein
RN.10748 2,9 3,9 5,5 cd4 antigen
RN.48861 5,2 4,8 3,6 vav 1 oncogene
RN.40136 3,5 4,3 3,2 transforming growth factor, beta 1
  1. *Only those genes and their corresponding functional classes found specifically enriched and significantly associated with epileptogenesis are shown (P-values ≤ 0.001, according to the Fisher Exact Test for functional enrichment analysis). Expression data is given as fold change from control, at the three time points analyzed after SE (D3 = three days after SE; D7 = seven days after SE; Chronic = immediately after the first spontaneous seizure).